Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 9, 2026

Personalized Peptide Arrays for Detection of HLA Alloantibodies in Organ Transplantation
08:07

Personalized Peptide Arrays for Detection of HLA Alloantibodies in Organ Transplantation

Published on: September 6, 2017

Biopsy-based Transcriptomics in Banff 2022 Antibody Mediated Rejection Categories.

Petra Hruba1, Eva Girmanova1, Dusan Harmacek2

  • 1Transplant Laboratory, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.

Kidney International Reports
|June 8, 2026
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An Unusual Cause of Oxalate Nephropathy: Acute Kidney Injury After Ingestion of Dried Bilimbi Fruit.

Cureus·2026
Same author

New-Onset ANCA-Associated Vasculitis in Pregnancy Successfully Treated With Rituximab: A Case Report and Literature Review.

Kidney medicine·2026
Same author

Impact of older donor age in kidney transplants in a biopsy-based observational study.

JCI insight·2026
Same author

Green CKD care: 10 tips to make nephrology outpatient clinics more environmentally sustainable.

Clinical kidney journal·2026
Same author

Corrigendum to "Improving the histologic detection of donor-specific antibody-negative antibody-mediated rejection in kidney transplants" [American Journal of Transplantation Volume 26, Issue 1, January 2026, Pages 117-130].

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2026
Same author

Absolute and Fractional Donor-Derived Cell-Free DNA in the Follow-Up of Kidney Allograft Rejection.

HLA·2026
Same journal

Renal Allograft Sympathetic Reinnervation and Possible Impact on Cardiovascular Risk Profile and Graft Function.

Kidney international reports·2026
Same journal

Randomized Crossover Trial of Low Sodium Dialysate on Tissue Sodium Accumulation in Hemodialysis.

Kidney international reports·2026
Same journal

Circulating Antinephrin Antibodies in Adult Chinese Patients With IgAN and Nephrotic-Range Proteinuria.

Kidney international reports·2026
Same journal

Ultrasensitive Immunoassay Using a Novel Galactose-Deficient IgA1 Antibody and Its Clinical Application in the Diagnosis of IgAN.

Kidney international reports·2026
Same journal

Association of IgG N-Glycans With Adverse Outcomes in CKD.

Kidney international reports·2026
Same journal

Urinary Soluble CD163: A Dynamic Biomarker for Monitoring Treatment Response and Relapse in IgA Nephropathy.

Kidney international reports·2026
See all related articles
This summary is machine-generated.

Biopsy-based transcriptomics (BBT) effectively diagnoses microvascular inflammation (MVI) in kidney transplants, especially in cases of probable antibody-mediated rejection (AMR). This molecular approach shows promise for refining AMR diagnostics beyond current histological standards.

Area of Science:

  • Nephrology
  • Transplant Immunology
  • Molecular Diagnostics

Background:

  • Biopsy-based transcriptomics (BBT) is a valuable tool for diagnosing antibody-mediated rejection (AMR) in kidney allografts.
  • However, its utility in validating Banff 2022 classifications for probable AMR and microvascular inflammation (MVI) associated with donor-specific antibodies (DSA) and C4d requires further investigation.

Purpose of the Study:

  • To evaluate the performance of BBT in classifying various forms of AMR, including probable AMR and MVI, using a large cohort of kidney allograft biopsies.
  • To compare the diagnostic accuracy of molecular markers with traditional histological assessments for predicting long-term graft survival.

Main Methods:

  • Analysis of 562 kidney allograft biopsies using histology and the Molecular Microscope Diagnostic System (MMDx).
Keywords:
Banff classificationantibody-mediated rejectionbiopsy-based transcript diagnosticskidney allograft biopsiesmicrovascular inflammation

Related Experiment Videos

Last Updated: Jun 9, 2026

Personalized Peptide Arrays for Detection of HLA Alloantibodies in Organ Transplantation
08:07

Personalized Peptide Arrays for Detection of HLA Alloantibodies in Organ Transplantation

Published on: September 6, 2017

  • Biopsies were categorized into active AMR spectrum lesions, combined active-chronic lesions with transplant glomerulopathy (cg), chronic AMR, and controls.
  • Classification involved assessing active AMR, probable AMR, MVI (with or without cg), and DSA-/C4d- status.

    • Main Results:

    • Molecular AMR was detected in a significant proportion of biopsies with active AMR (51%), MVI (43-56%), and chronic-active AMR (63%), but was rare in chronic AMR (6%).
    • AMR probability classifier (AMRprob) scores were elevated in probable AMR and MVI groups compared to controls, and comparable across active AMR, chronic-active AMR, and MVI groups.
    • Both molecular and histological models demonstrated similar performance in predicting 3-year graft survival, with concordance rates of 0.84 and 0.82, respectively.

    Conclusions:

    • BBT primarily reflects microvascular inflammation (MVI) rather than donor-specific antibodies (DSA) in kidney allografts.
    • BBT is particularly informative for diagnosing probable AMR and MVI-positive biopsies.
    • Molecular and histological assessments show comparable efficacy in predicting long-term kidney allograft survival.